Biotech News

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Atea (AVIR)Atea2026-08-12 20:05 ESTEarnings

Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM/RZR for Treatment of HCV C-FORWARD Phase 3 Trial Outside North America on Track with Topline Results Expected Early Q1 2027

Related news

AVIRAtea2026-08-05 11:00 EST

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

AVIRAtea2026-05-12 20:06 EST

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

ENTAEnanta Pharmaceuticals2026-05-11 20:01 EST

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026

ENTAEnanta Pharmaceuticals2025-11-17 21:01 EST

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025

ASMBAssembly Biosciences2026-08-13 20:00 EST

Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates

ANTXAN2 Therapeutics2026-08-11 20:00 EST

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

IMNNImunon2026-08-11 12:00 EST

IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update

SCYXSCYNEXIS2026-08-10 20:30 EST

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

BRNSBarinthus Biotherapeutics2026-08-06 12:00 EST

Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

VIRIVirios Therapeutics2026-08-13 12:30 EST

Dogwood Therapeutics Announces Second Quarter 2026 Financial Results

View all latest news

Atea

Oral Antiviral Therapeutics Atea Pharmaceuticals develops oral antiviral therapies for serious viral diseases. Its pipeline is built around nucleotide and nucleoside analog chemistry and combination treatment strategies. Bemnifosbuvir and Ruzasvir The lead regimen combines the nucleotide polymerase inhibitor bemnifosbuvir with the NS5A...

Recent company news

AVIRAtea2026-08-12 20:05 EST

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

AVIRAtea2026-08-05 11:00 EST

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

AVIRAtea2026-07-28 11:00 EST

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

AVIRAtea2026-07-14 11:00 EST

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

AVIRAtea2026-06-25 11:00 EST

Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Stock data

Close: 5.22 USD
Market cap: 341.72M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States